A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-09-23

AUTHORS

T B Dorff, S Groshen, D D Tsao-Wei, S Xiong, M E Gross, N Vogelzang, D I Quinn, J K Pinski

ABSTRACT

Background:Men with biochemical recurrence (BCR) of prostate cancer are typically observed or treated with androgen-deprivation therapy. Non-hormonal, non-toxic treatments to slow the rise of PSA are desirable. We studied a combination herbal supplement, Prostate Health Cocktail (PHC), in prostate cancer cell lines and in a population of men with BCR.Methods:PC3, LAPC3 and LNCaP cells were incubated with increasing concentrations of PHC suspension. Men previously treated for prostate cancer with surgery, radiation or both with rising PSA but no radiographic metastases were treated with three capsules of PHC daily; the primary end point was 50% PSA decline. Circulating tumor cells (CTCs) were identified using parylene membrane filters.Results:PHC showed a strong dose-dependent anti-proliferative effect in androgen-sensitive and independent cell lines in vitro and suppression of androgen receptor expression. Forty eligible patients were enrolled in the clinical trial. Median baseline PSA was 2.8 ng ml−1 (1.1–84.1) and 15 men (38%) had a PSA decline on study (1–55% reduction); 25 (62%) had rising PSA on study. The median duration of PSA stability was 6.4 months. Two patients had grade 2/3 transaminitis; the only other grade 2 toxicities were hyperglycemia, hypercalcemia and flatulence. There were no significant changes in testosterone or dihydrotestosterone. CTCs were identified in 19 men (47%).Conclusions:Although the primary end point was not met, PHC was well tolerated and was associated with PSA declines and stabilization in a significant number of patients. We believe this is the first report of detecting CTCs in men with BCR prostate cancer. Randomized studies are needed to better define the effect of PHC in men with BCR. More... »

PAGES

359-365

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/pcan.2014.37

DOI

http://dx.doi.org/10.1038/pcan.2014.37

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001199978

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25245366


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biochemical Phenomena", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blotting, Western", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phytotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorff", 
        "givenName": "T B", 
        "id": "sg:person.01007666002.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Groshen", 
        "givenName": "S", 
        "id": "sg:person.011144220037.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011144220037.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsao-Wei", 
        "givenName": "D D", 
        "id": "sg:person.010304735667.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010304735667.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "S", 
        "id": "sg:person.01061024216.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061024216.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Keck School of Medicine, Westside Prostate Cancer Center, Center for Applied Molecular Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Keck School of Medicine, Westside Prostate Cancer Center, Center for Applied Molecular Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gross", 
        "givenName": "M E", 
        "id": "sg:person.0623540223.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623540223.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA", 
          "id": "http://www.grid.ac/institutes/grid.428254.d", 
          "name": [
            "Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vogelzang", 
        "givenName": "N", 
        "id": "sg:person.01222473575.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222473575.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Department of Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "D I", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Department of Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pinski", 
        "givenName": "J K", 
        "id": "sg:person.0600562331.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600562331.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/pcan.2012.20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006305443", 
          "https://doi.org/10.1038/pcan.2012.20"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-09-23", 
    "datePublishedReg": "2014-09-23", 
    "description": "Background:Men with biochemical recurrence (BCR) of prostate cancer are typically observed or treated with androgen-deprivation therapy. Non-hormonal, non-toxic treatments to slow the rise of PSA are desirable. We studied a combination herbal supplement, Prostate Health Cocktail (PHC), in prostate cancer cell lines and in a population of men with BCR.Methods:PC3, LAPC3 and LNCaP cells were incubated with increasing concentrations of PHC suspension. Men previously treated for prostate cancer with surgery, radiation or both with rising PSA but no radiographic metastases were treated with three capsules of PHC daily; the primary end point was 50% PSA decline. Circulating tumor cells (CTCs) were identified using parylene membrane filters.Results:PHC showed a strong dose-dependent anti-proliferative effect in androgen-sensitive and independent cell lines in vitro and suppression of androgen receptor expression. Forty eligible patients were enrolled in the clinical trial. Median baseline PSA was 2.8\u2009ng\u2009ml\u22121 (1.1\u201384.1) and 15 men (38%) had a PSA decline on study (1\u201355% reduction); 25 (62%) had rising PSA on study. The median duration of PSA stability was 6.4 months. Two patients had grade 2/3 transaminitis; the only other grade 2 toxicities were hyperglycemia, hypercalcemia and flatulence. There were no significant changes in testosterone or dihydrotestosterone. CTCs were identified in 19 men (47%).Conclusions:Although the primary end point was not met, PHC was well tolerated and was associated with PSA declines and stabilization in a significant number of patients. We believe this is the first report of detecting CTCs in men with BCR prostate cancer. Randomized studies are needed to better define the effect of PHC in men with BCR.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/pcan.2014.37", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438805", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1119336", 
        "issn": [
          "1365-7852", 
          "1476-5608"
        ], 
        "name": "Prostate Cancer and Prostatic Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "keywords": [
      "primary end point", 
      "biochemical recurrence", 
      "prostate cancer", 
      "PSA decline", 
      "herbal supplements", 
      "biochemically recurrent prostate cancer", 
      "end point", 
      "Median baseline PSA", 
      "androgen deprivation therapy", 
      "grade 2 toxicity", 
      "phase II trial", 
      "androgen receptor expression", 
      "recurrent prostate cancer", 
      "prostate cancer cell lines", 
      "dose-dependent anti-proliferative effect", 
      "population of men", 
      "BCR prostate cancer", 
      "cell lines", 
      "anti-proliferative effects", 
      "non-toxic treatment", 
      "radiographic metastases", 
      "eligible patients", 
      "PSA stability", 
      "cancer cell lines", 
      "II trial", 
      "baseline PSA", 
      "median duration", 
      "randomized study", 
      "clinical trials", 
      "receptor expression", 
      "LNCaP cells", 
      "tumor cells", 
      "patients", 
      "cancer", 
      "PSA", 
      "men", 
      "independent cell lines", 
      "trials", 
      "significant changes", 
      "CTCs", 
      "significant number", 
      "first report", 
      "supplements", 
      "transaminitis", 
      "hypercalcemia", 
      "cells", 
      "hyperglycemia", 
      "surgery", 
      "recurrence", 
      "metastasis", 
      "dihydrotestosterone", 
      "therapy", 
      "flatulence", 
      "testosterone", 
      "months", 
      "study", 
      "treatment", 
      "decline", 
      "vitro", 
      "toxicity", 
      "duration", 
      "capsule", 
      "PC3", 
      "report", 
      "effect", 
      "cocktail", 
      "population", 
      "expression", 
      "suppression", 
      "lines", 
      "changes", 
      "concentration", 
      "number", 
      "point", 
      "rise", 
      "stabilization", 
      "membrane filters", 
      "radiation", 
      "suspension", 
      "stability", 
      "filter"
    ], 
    "name": "A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer", 
    "pagination": "359-365", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001199978"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/pcan.2014.37"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25245366"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/pcan.2014.37", 
      "https://app.dimensions.ai/details/publication/pub.1001199978"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_621.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/pcan.2014.37"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/pcan.2014.37'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/pcan.2014.37'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/pcan.2014.37'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/pcan.2014.37'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      121 URIs      111 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/pcan.2014.37 schema:about N09432d51d1a64a38b933b751ac28ceb2
2 N1b8a2ab118b4446ea2abac6147990f43
3 N41a65414e5a0439a81ea102b99780143
4 N66026357a7894583a998ac9fd035e073
5 N8eb92d678e6843aa9e04ee956a82823f
6 N9639b63a95814698b987ab54c84a14af
7 Na1cd60f82c8642918bd63c7c9190b72e
8 Na55610e9210f4ad5b2af9941055a333d
9 Nade54c3c62c043569f45cf7fbd879a13
10 Ndc8e1b478e0b4a4db8c34599333c030b
11 Ndff86570bdae4067bf8c629cd053a868
12 Nf266d373ebbd4f9cb3c465236e9262ad
13 Nff85604c7b3c4983a481388ef9c202d6
14 anzsrc-for:11
15 anzsrc-for:1103
16 anzsrc-for:1112
17 schema:author Ncfa016344bab4bfd8c4955670f1e3644
18 schema:citation sg:pub.10.1038/pcan.2012.20
19 schema:datePublished 2014-09-23
20 schema:datePublishedReg 2014-09-23
21 schema:description Background:Men with biochemical recurrence (BCR) of prostate cancer are typically observed or treated with androgen-deprivation therapy. Non-hormonal, non-toxic treatments to slow the rise of PSA are desirable. We studied a combination herbal supplement, Prostate Health Cocktail (PHC), in prostate cancer cell lines and in a population of men with BCR.Methods:PC3, LAPC3 and LNCaP cells were incubated with increasing concentrations of PHC suspension. Men previously treated for prostate cancer with surgery, radiation or both with rising PSA but no radiographic metastases were treated with three capsules of PHC daily; the primary end point was 50% PSA decline. Circulating tumor cells (CTCs) were identified using parylene membrane filters.Results:PHC showed a strong dose-dependent anti-proliferative effect in androgen-sensitive and independent cell lines in vitro and suppression of androgen receptor expression. Forty eligible patients were enrolled in the clinical trial. Median baseline PSA was 2.8 ng ml−1 (1.1–84.1) and 15 men (38%) had a PSA decline on study (1–55% reduction); 25 (62%) had rising PSA on study. The median duration of PSA stability was 6.4 months. Two patients had grade 2/3 transaminitis; the only other grade 2 toxicities were hyperglycemia, hypercalcemia and flatulence. There were no significant changes in testosterone or dihydrotestosterone. CTCs were identified in 19 men (47%).Conclusions:Although the primary end point was not met, PHC was well tolerated and was associated with PSA declines and stabilization in a significant number of patients. We believe this is the first report of detecting CTCs in men with BCR prostate cancer. Randomized studies are needed to better define the effect of PHC in men with BCR.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N3715f3c20e1642cba9449e2b82cf50ae
25 N38b780f1665043f0a06bdc784edb9a08
26 sg:journal.1119336
27 schema:keywords BCR prostate cancer
28 CTCs
29 II trial
30 LNCaP cells
31 Median baseline PSA
32 PC3
33 PSA
34 PSA decline
35 PSA stability
36 androgen deprivation therapy
37 androgen receptor expression
38 anti-proliferative effects
39 baseline PSA
40 biochemical recurrence
41 biochemically recurrent prostate cancer
42 cancer
43 cancer cell lines
44 capsule
45 cell lines
46 cells
47 changes
48 clinical trials
49 cocktail
50 concentration
51 decline
52 dihydrotestosterone
53 dose-dependent anti-proliferative effect
54 duration
55 effect
56 eligible patients
57 end point
58 expression
59 filter
60 first report
61 flatulence
62 grade 2 toxicity
63 herbal supplements
64 hypercalcemia
65 hyperglycemia
66 independent cell lines
67 lines
68 median duration
69 membrane filters
70 men
71 metastasis
72 months
73 non-toxic treatment
74 number
75 patients
76 phase II trial
77 point
78 population
79 population of men
80 primary end point
81 prostate cancer
82 prostate cancer cell lines
83 radiation
84 radiographic metastases
85 randomized study
86 receptor expression
87 recurrence
88 recurrent prostate cancer
89 report
90 rise
91 significant changes
92 significant number
93 stability
94 stabilization
95 study
96 supplements
97 suppression
98 surgery
99 suspension
100 testosterone
101 therapy
102 toxicity
103 transaminitis
104 treatment
105 trials
106 tumor cells
107 vitro
108 schema:name A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer
109 schema:pagination 359-365
110 schema:productId N1f8136139e4e469397fa14b2fa62634f
111 N689f1969cd5d40b481d4df1850673c2d
112 Nfd96d27331d4481baf6264f381d4cd49
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001199978
114 https://doi.org/10.1038/pcan.2014.37
115 schema:sdDatePublished 2022-09-02T15:57
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher N0781eaacd03a4d9ab910e8b538493dcf
118 schema:url https://doi.org/10.1038/pcan.2014.37
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N0781eaacd03a4d9ab910e8b538493dcf schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 N09432d51d1a64a38b933b751ac28ceb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Blotting, Western
126 rdf:type schema:DefinedTerm
127 N1b8a2ab118b4446ea2abac6147990f43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Cell Line, Tumor
129 rdf:type schema:DefinedTerm
130 N1f8136139e4e469397fa14b2fa62634f schema:name pubmed_id
131 schema:value 25245366
132 rdf:type schema:PropertyValue
133 N31ed36038e0442759df90d94c0535a6b rdf:first sg:person.0600562331.16
134 rdf:rest rdf:nil
135 N3715f3c20e1642cba9449e2b82cf50ae schema:volumeNumber 17
136 rdf:type schema:PublicationVolume
137 N38b780f1665043f0a06bdc784edb9a08 schema:issueNumber 4
138 rdf:type schema:PublicationIssue
139 N41a65414e5a0439a81ea102b99780143 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Aged
141 rdf:type schema:DefinedTerm
142 N66026357a7894583a998ac9fd035e073 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Male
144 rdf:type schema:DefinedTerm
145 N689f1969cd5d40b481d4df1850673c2d schema:name dimensions_id
146 schema:value pub.1001199978
147 rdf:type schema:PropertyValue
148 N69422a316a674654a2064ce8d9f325b0 rdf:first sg:person.0623540223.07
149 rdf:rest Nfebe47557977424fb3b6d45285527796
150 N8eb92d678e6843aa9e04ee956a82823f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Biochemical Phenomena
152 rdf:type schema:DefinedTerm
153 N9639b63a95814698b987ab54c84a14af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Phytotherapy
155 rdf:type schema:DefinedTerm
156 N9d2a1edeaf7f436eabdaec0181e585d3 rdf:first sg:person.01061024216.54
157 rdf:rest N69422a316a674654a2064ce8d9f325b0
158 Na1cd60f82c8642918bd63c7c9190b72e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Humans
160 rdf:type schema:DefinedTerm
161 Na55610e9210f4ad5b2af9941055a333d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Neoplasm Recurrence, Local
163 rdf:type schema:DefinedTerm
164 Na951646b6caf4ea8b94a39fb6df5b177 rdf:first sg:person.010304735667.62
165 rdf:rest N9d2a1edeaf7f436eabdaec0181e585d3
166 Nade54c3c62c043569f45cf7fbd879a13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Prostatic Neoplasms
168 rdf:type schema:DefinedTerm
169 Nc75626edf7b543e283d03986198abb54 rdf:first sg:person.01013134010.15
170 rdf:rest N31ed36038e0442759df90d94c0535a6b
171 Ncfa016344bab4bfd8c4955670f1e3644 rdf:first sg:person.01007666002.23
172 rdf:rest Ne6417b1cf1e64a05ace5c69002f51e3f
173 Ndc8e1b478e0b4a4db8c34599333c030b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Middle Aged
175 rdf:type schema:DefinedTerm
176 Ndff86570bdae4067bf8c629cd053a868 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Aged, 80 and over
178 rdf:type schema:DefinedTerm
179 Ne6417b1cf1e64a05ace5c69002f51e3f rdf:first sg:person.011144220037.86
180 rdf:rest Na951646b6caf4ea8b94a39fb6df5b177
181 Nf266d373ebbd4f9cb3c465236e9262ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Prostate-Specific Antigen
183 rdf:type schema:DefinedTerm
184 Nfd96d27331d4481baf6264f381d4cd49 schema:name doi
185 schema:value 10.1038/pcan.2014.37
186 rdf:type schema:PropertyValue
187 Nfebe47557977424fb3b6d45285527796 rdf:first sg:person.01222473575.87
188 rdf:rest Nc75626edf7b543e283d03986198abb54
189 Nff85604c7b3c4983a481388ef9c202d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Cell Proliferation
191 rdf:type schema:DefinedTerm
192 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
193 schema:name Medical and Health Sciences
194 rdf:type schema:DefinedTerm
195 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
196 schema:name Clinical Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
199 schema:name Oncology and Carcinogenesis
200 rdf:type schema:DefinedTerm
201 sg:grant.2438805 http://pending.schema.org/fundedItem sg:pub.10.1038/pcan.2014.37
202 rdf:type schema:MonetaryGrant
203 sg:journal.1119336 schema:issn 1365-7852
204 1476-5608
205 schema:name Prostate Cancer and Prostatic Diseases
206 schema:publisher Springer Nature
207 rdf:type schema:Periodical
208 sg:person.01007666002.23 schema:affiliation grid-institutes:grid.42505.36
209 schema:familyName Dorff
210 schema:givenName T B
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23
212 rdf:type schema:Person
213 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
214 schema:familyName Quinn
215 schema:givenName D I
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
217 rdf:type schema:Person
218 sg:person.010304735667.62 schema:affiliation grid-institutes:grid.42505.36
219 schema:familyName Tsao-Wei
220 schema:givenName D D
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010304735667.62
222 rdf:type schema:Person
223 sg:person.01061024216.54 schema:affiliation grid-institutes:grid.42505.36
224 schema:familyName Xiong
225 schema:givenName S
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061024216.54
227 rdf:type schema:Person
228 sg:person.011144220037.86 schema:affiliation grid-institutes:grid.42505.36
229 schema:familyName Groshen
230 schema:givenName S
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011144220037.86
232 rdf:type schema:Person
233 sg:person.01222473575.87 schema:affiliation grid-institutes:grid.428254.d
234 schema:familyName Vogelzang
235 schema:givenName N
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222473575.87
237 rdf:type schema:Person
238 sg:person.0600562331.16 schema:affiliation grid-institutes:grid.42505.36
239 schema:familyName Pinski
240 schema:givenName J K
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600562331.16
242 rdf:type schema:Person
243 sg:person.0623540223.07 schema:affiliation grid-institutes:grid.42505.36
244 schema:familyName Gross
245 schema:givenName M E
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623540223.07
247 rdf:type schema:Person
248 sg:pub.10.1038/pcan.2012.20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006305443
249 https://doi.org/10.1038/pcan.2012.20
250 rdf:type schema:CreativeWork
251 grid-institutes:grid.42505.36 schema:alternateName Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
252 Division of Medical Oncology, Department of Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
253 Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
254 Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
255 Keck School of Medicine, Westside Prostate Cancer Center, Center for Applied Molecular Medicine, University of Southern California, Los Angeles, CA, USA
256 schema:name Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
257 Division of Medical Oncology, Department of Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
258 Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
259 Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
260 Keck School of Medicine, Westside Prostate Cancer Center, Center for Applied Molecular Medicine, University of Southern California, Los Angeles, CA, USA
261 rdf:type schema:Organization
262 grid-institutes:grid.428254.d schema:alternateName Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA
263 schema:name Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...